The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
Several Bevacizumab products are approved for clinical use, with many others in late-stage clinical development worldwide. To aid the harmonization of potency assessment across different Bevacizumab products, the first World Health Organization (WHO) International Standard (IS) for Bevacizumab has b...
Guardado en:
Autores principales: | Haiyan Jia, Parvathy Harikumar, Eleanor Atkinson, Peter Rigsby, Meenu Wadhwa |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6b8aebf576ca4520ab6ca16d6572b462 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
por: Rui Wan, et al.
Publicado: (2021) -
Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
por: Liu J, et al.
Publicado: (2019) -
A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA.hy926 endothelial cell line
por: ARANDA,EVELYN, et al.
Publicado: (2009) -
Linc-OIP5 in the breast cancer cells regulates angiogenesis of human umbilical vein endothelial cells through YAP1/Notch/NRP1 signaling circuit at a tumor microenvironment
por: Zhu,Qing, et al.
Publicado: (2020) -
Interaction of hydroxyapatite nanoparticles with endothelial cells: internalization and inhibition of angiogenesis in vitro through the PI3K/Akt pathway
por: Shi X, et al.
Publicado: (2017)